UCB reformulating Parkinson's patch to eliminate crystals

Biopharma company UCB will reformulate its Parkinson's disease and restless leg syndrome drug Neupro before making it available on the U.S. market, per recommendation of the FDA. The regulator's decision answers an NDA supplement submitted by the Belgian drugmaker in June 2009, which proposed new refrigerated storage conditions to alleviate crystallization on the transdermal patches. The FDA agreed that improved storage helped alleviate the problem, but reformulation provided "definitive resolution." Item

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.